tradingkey.logo

Celularity Inc

CELUW
0.020USD
+0.003+21.21%
Close ETQuotes delayed by 15 min
0.00Market Cap
--P/E TTM

Celularity Inc

0.020
+0.003+21.21%

More Details of Celularity Inc Company

Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).

Celularity Inc Info

Ticker SymbolCELUW
Company nameCelularity Inc
IPO dateMay 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address170 Park Ave
CityFLORHAM PARK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07932
Phone19087682170
Websitehttps://celularity.com/
Ticker SymbolCELUW
IPO dateMay 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.

Company Executives of Celularity Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
24
2.39M
0.00%
-1.27M
2025Q3
27
2.39M
0.00%
+8.32K
2025Q2
27
2.38M
0.00%
-98.84K
2025Q1
31
2.48M
0.00%
-2.12M
2024Q4
30
2.60M
0.00%
-201.65K
2024Q3
31
2.80M
0.00%
+233.05K
2024Q2
32
2.67M
0.00%
-17.59K
2024Q1
32
2.68M
0.00%
-2.18M
2023Q4
31
3.99M
0.00%
-554.70K
2023Q3
31
4.57M
0.00%
-939.92K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Clear Street Group Inc
11.91K
0%
+11.91K
--
Sep 30, 2025
Walleye Capital LLC
835.19K
0%
-14.92K
-1.75%
Sep 30, 2025
Linden Advisors L.P.
550.12K
0%
--
--
Sep 30, 2025
Healthcare Of Ontario Pension Plan
350.00K
0%
--
--
Sep 30, 2025
Peak6 Capital Management LLC
171.36K
0%
--
--
Sep 30, 2025
Davidson Kempner Capital Management LP
150.80K
0%
--
--
Sep 30, 2025
Context Capital Management LLC
150.00K
0%
--
--
Sep 30, 2025
Corient Private Wealth LLC
55.00K
0%
--
--
Sep 30, 2025
EMFO, LLC
50.00K
0%
--
--
Jun 30, 2024
Clear Street LLC
11.91K
0%
--
--
Jun 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data

FAQs

Who are the top five shareholders of Celularity Inc?

The top five shareholders of Celularity Inc are:
Clear Street Group Inc holds 11.91K shares, accounting for 0.00% of the total shares.
Walleye Capital LLC holds 835.19K shares, accounting for 0.00% of the total shares.
Linden Advisors L.P. holds 550.12K shares, accounting for 0.00% of the total shares.
Healthcare Of Ontario Pension Plan holds 350.00K shares, accounting for 0.00% of the total shares.
Peak6 Capital Management LLC holds 171.36K shares, accounting for 0.00% of the total shares.

What are the top three shareholder types of Celularity Inc?

The top three shareholder types of Celularity Inc are:
Other

How many institutions hold shares of Celularity Inc (CELUW)?

As of 2025Q4, 24 institutions hold shares of Celularity Inc, with a combined market value of approximately 2.39M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.

What is the biggest source of revenue for Celularity Inc?

In --, the -- business generated the highest revenue for Celularity Inc, amounting to -- and accounting for --% of total revenue.
KeyAI